The person who says something is impossible
should not interrupt the person who is doing it
.” 

—Chinese proverb

Portfolio

 

 Current:  

Comentis

About: Athenagen (later renamed CoMentis)* is dedicated to the discovery and development of small-molecule drugs to treat Alzheimer’s disease. www.comentis.com

Founded: April, 2005 (renamed CoMentis following merger with Zapaq, Inc. in 2007) (South San Francisco, CA)
Total funds raised; $87 MM
Other Investors: Sanderling Ventures, Clarus Ventures, Index ventures, Charter Life Sciences, Astellas Pharma, Inc. and Astellas Venture Capital LLC

  
  

Armetheon

About: Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) drugs that are direct inhibitors of thrombin or Factor Xa, tecarfarin with one Phase III completed, could be used in patients with (i) prosthetic heart valves, and/or (ii) who have renal dysfunction (with one Phase III completed). Planning to grow the company over time with additional pipeline. www.armetheon.com

Founded: October, 2011 (Milpitas, CA)
Total funds raised; $33 MM
Other Investors: Capital TEN II, Hercules Bioventures, CDIB
 Healthcare, CDIB & Partners, AshHill Biomedical Investments, iD SoftCapital, AmKey Ventures, and eminent biotech entrepreneurs and pharmaceutical executives.

  

 renexxion logo

About: Renexxion is a pharmaceutical company developing potentially a best-in-class oral safe and effective 5HT4 agonist for gastrointestinal (GI) disorders. These include upper GI (such as sGERD, PPI-resistant GERD, gastroparesis) and lower GI (such as chronic idiopathic constipation) disorders (currently Phase III ready).  www.renexxion.com

Founded: September, 2014 (Menlo Park, CA)
Total funds raised: Not Disclosed
Other Investors:
 Founders

  
Past:  

 

About: Altheos, Inc. was focused on developing novel ophthalmic drugs for unmet clinical need in glaucoma.

Founded: April, 2009 (South San Francisco, CA)
Total funds raised; $32.5MM
Investors: Bay City Capital, Canaan Partners, Novo, Life Science Angels, angel investors and founders

   
   

*previously funded and currently managed

“So many of our dreams at first seem impossible, then they seem improbable, and then, when we summon the will, they soon become inevitable.” - Christopher Reeve